[go: up one dir, main page]

EP1583519A1 - Compactage haute pression pour formulations pharmaceutiques - Google Patents

Compactage haute pression pour formulations pharmaceutiques

Info

Publication number
EP1583519A1
EP1583519A1 EP03800248A EP03800248A EP1583519A1 EP 1583519 A1 EP1583519 A1 EP 1583519A1 EP 03800248 A EP03800248 A EP 03800248A EP 03800248 A EP03800248 A EP 03800248A EP 1583519 A1 EP1583519 A1 EP 1583519A1
Authority
EP
European Patent Office
Prior art keywords
pressure
gpa
fused
particles
active pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP03800248A
Other languages
German (de)
English (en)
Inventor
Thomas J. Smith
Gene Gauzer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
St James Associates Llc/Faber Research Series
Original Assignee
St James Associates Llc/Faber Research Series
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by St James Associates Llc/Faber Research Series filed Critical St James Associates Llc/Faber Research Series
Publication of EP1583519A1 publication Critical patent/EP1583519A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient

Definitions

  • the invention relates to the field of pharmacology and, in particular, to sustained-release formulations for active pharmaceutical ingredients.
  • the invention also relates to methods for preparing such formulations by high pressure compaction of an active pharmaceutical ingredient.
  • sustained-release systems in the prior art have employed a finely milled or micronized preparation of the active pharmaceutical ingredient as a starting point in the formulations.
  • the release of the active pharmaceutical ingredient into the body is then controlled using matrices, membranes or other inactive ingredients or devices.
  • examples of methods and devices known in the art for sustained release formulations include liposomes, bioerodible matrices (e.g., PLA/PGLA matrices), drug-permeable implants (e.g., U.S. Pat. No. 3,993,073 to Zaffaroni), implants with drug-permeable and drug-impermeable membranes (e.g., U.S. Pat. No. 5,378,475 to Smith et al.), and osmotic drug delivery systems (e.g., U.S. Pat. No.4,439,196 to Higuchi).
  • Prior art sustained-release delivery systems with large particles of an active pharmaceutical ingredient such as insulin, corticosteroids, or penicillins, employ techniques as solvation crystallization, thermal crystallization, or seeding crystallization to produce the larger particles.
  • the pressure is maintained for a period of between 30 sec. and 10 min. In other embodiments, the pressure is maintained for a period of between 60 sec. and 5 min. In yet other embodiments, the pressure is maintained for a period of between 90 sec. and 3 min.
  • the sample prior to compaction includes micronized particles including the active pharmaceutical ingredient.
  • the invention provides pharmaceutical preparations of pressure-fused particles comprising an active pharmaceutical ingredient in which the pressure-fused particles include an active pharmaceutical ingredient subjected to high pressure compaction at a pressure of between 0.1 GPa and 10 GPa. In some embodiments, the pressure is between 0.5 GPa and 7.5 GPa. In other embodiments, the pressure is between 1 GPa and 5 GPa.
  • the pressure-fused particles have a maximum dimension between 20 ⁇ m and 800 ⁇ m. In other embodiments, the pressure-fused particles have a maximum dimension between 40 ⁇ m and 400 ⁇ m. In yet other embodiments, the pressure-fused particles have a maximum dimension between 100 ⁇ m and 250 ⁇ m.
  • Figure 2 presents data regarding the in vivo release of the active pharmaceutical nifedipine from a compacted sample including pressure-fused microparticles of the invention over a sustained-release period.
  • the particles of the invention are substantially spherical in some embodiments, the particles can be any solid geometric shape which is not inconsistent with the principles of the invention, including, without limitation, ellipsoids, cylinders, polyhedrons, disks and irregular shapes.
  • Disk means any solid body which is significantly smaller in a first dimension relative to the two perpendicular dimensions. Such bodies may be variously described as disks, wafers, or planar bodies, including, without limitation, bodies which are circular, elliptical or polygonal in the plane perpendicular to the first dimension.
  • Semi-Permeable As used herein, the term “semi-permeable” means permeable to some molecules but not to others. As used herein, semi-permeable polymeric coatings are permeable to at least water and the active pharmaceutical ingredient within the particles of the invention.
  • Biocompatible means characterized by not causing a toxic, injurious or immunological response when brought into contact with living tissue, particularly human or other mammalian tissue.
  • Biodegradable means capable of partially or completely dissolving or decomposing in living tissue, particularly human or other mammalian tissue. Biodegradable compounds can be degraded by any mechanism, including, without limitation, hydrolysis, catalysis and enzymatic action.
  • Pseudo-Zero-Order Kinetics As used herein, the term "pseudo-zero-order kinetics" means sustained-release of the active pharmaceutical ingredient which exhibits kinetics which is zero-order (i.e., independent of concentration) or between zero-order and first order (i.e., proportional to concentration) kinetics over the sustained-release period, where the concentration is based on the total amount of the active pharmaceutical ingredient contained within the particles. In some embodiments, the release exhibits kinetics which are less than proportional to the square root of the concentration of the active pharmaceutical ingredient over the sustained-release period.
  • a variable which is described as having values between 0 and 2 can take the values 0, 1 or 2 if the variable is inherently discrete, and can take the values 0.0, 0.1, 0.01, 0.001, or any other real values > 0 and ⁇ 2 if the variable is inherently continuous.
  • the present invention depends, in part, upon the discovery that the application of high pressure compaction to powdered or micronized pharmaceutical preparations can cause physical but non-chemical transformations to an alternative state with substantially slower rates of dissolution and, consequently, increased utility in the preparation of sustained-release formulations.
  • pharmaceutical preparations subjected to high pressure compaction exhibit dissolution kinetics which are superior to conventional crystalline or amorphous packed powder preparations for sustained-release administration of active pharmaceutical ingredients.
  • high pressure compaction causes a physical but non-chemical transformation of state to form pressure-fused particles which, in some embodiments, exhibit hyaline or glassy characteristics but, in other embodiments, retain crystalline or amorphous characteristics.
  • the resultant pressure-fused particles have different dissolution characteristics and, in particular, slower rates of dissolution.
  • the amount of pressure is sufficient to produce a compacted sample having a density of between 1 g/cm 3 and 40 g/cm 3 , between 2 g/cm 3 and 20 g/cm 3 , and between 4 g/cm 3 and 10 g/cm 3 . In some embodiments, the amount of pressure is sufficient to produce pressure-fused microparticles having a density of between 1 g/cm 3 and 40 g/cm 3 , between 2 g/cm 3 and 20 g/cm 3 , and between 4 g/cm 3 and 10 g/cm 3 .
  • the invention also depends, in part, upon the recognition that, if a larger particle of a pharmaceutical preparation is introduced, there will be a sustained-release effect due to the decreased surface area-to-volume ratio of the larger particles.
  • the particle if the particle is formulated to be substantially flat or planar, then the kinetics of drug release will more nearly approximate constant or zero-order kinetics.
  • the particles of the invention can be used for parenteral administration.
  • the administration will be by injection (e.g., subcutaneous, intravenous, intramuscular, intraocular), or by introduction to a wound site or during surgery (e.g., lavage or irrigation of a wound or surgical site).
  • the particles can be sufficiently small to form a suspension and, in certain embodiments, the particles can be sufficiently small for injection through a hypodermic needle.
  • the particles have a maximum dimension of between 20 ⁇ m and 800 ⁇ m, between 40 ⁇ m and 400 ⁇ m, or between 100 ⁇ m and 250 ⁇ m.
  • the resulting compacted sample can be subjected to sieving to obtain particles of a desired size.
  • the compacted sample can be pressed through a sieve with an exclusion limit of between 20 ⁇ m and 800 ⁇ m, between 40 ⁇ m and 400 ⁇ m, or between 100 ⁇ m and 250 ⁇ m.
  • the compacted samples or sieved particles can be subjected to milling to produce fused particles of smaller size or with different geometries. For example, in some embodiments, pressure-fused particles are milled to produce spheres whereas in other embodiments the pressure-fused particles are milled to produce disks.
  • biocompatible and biodegradable polymers examples include poly(lactic acid) (PLA), poly(glycolic acid) (PGA), poly(lactic-co-glycolic acid) (PLGA), poly( ⁇ -caprolactone) (PCL), poly(valerolactone) (PVL), poly( ⁇ -decalactone) (PDL), poly(l,4-dioxane-2,3-dione), poly(l,3-dioxane-2-one), poly(para-dioxanone) (PDS), poly(hydroxybutyric acid) (PHB), poly(hydroxyvaleric acid) (PHV), and poly( ⁇ -malic acid) (PMLA).
  • PLA poly(lactic acid)
  • PGA poly(glycolic acid)
  • PLA poly(lactic-co-glycolic acid)
  • PCL poly( ⁇ -caprolactone)
  • PVL poly(valerolactone)
  • PVL poly( ⁇ -decalactone)
  • PDS poly(
  • Non-limiting examples of anti-psychotics include benzodiazepines such as olanzapine (ZyprexaTM), clozapine, loxapine, and quetiapine; benzisoxazole derivatives such as risperidone (RisperdalTM) and molindone, and pimozide.
  • benzodiazepines such as olanzapine (ZyprexaTM), clozapine, loxapine, and quetiapine
  • benzisoxazole derivatives such as risperidone (RisperdalTM) and molindone, and pimozide.
  • Non-limiting examples of anti-epileptics include hydantoins such as dilantin; barbiturates such as phenobarbital; deoxybarbiturates such as primidone; iminostilbenes such as cabamazepine; succinimides such as ethosuximide; benzodiazepines such as clonazepam; as well as valproic acid, gabapentin, levetiracetam, tiagabine, topiramate and zonisamide.
  • hydantoins such as dilantin
  • barbiturates such as phenobarbital
  • deoxybarbiturates such as primidone
  • iminostilbenes such as cabamazepine
  • succinimides such as ethosuximide
  • benzodiazepines such as clonazepam
  • valproic acid gabapentin, levetiracetam, tiagabine, topiramate and zonisamide.
  • Non-limiting examples of anti-Parkinson agents include levodopa preparations such as levodopa benserazide and levodopa/carbidopa; ergot dopamine agonists such as bromocriptine, cabergoline, and pergolide; non-ergot dopamine agonists such pramipexole, ropinerole, and spomorphine; catechol-O-methyltransferase inhibitors such as entacapone and tolcapone; monoamine oxidase B inhibitors such as selegiline;
  • HIV protease inhibitors include ritonavir, indinavir, nelfinavir, saquinavir, amprenavir and lopinavir.
  • nucleoside reverse transcriptase inhibitors include the nucleoside-based reverse transcriptase inhibitors zidovudine, didanosine, stavudine, zalcitabine, lamuvidine, and abacavir, and the non-nucleoside-based reverse transcriptase inhibitors include delavirdine, efavirenez and nevirapine.
  • Non-limiting examples of taxanes include paclitaxel and docetaxel.
  • Non-limiting examples of alkylating agents include the nitrogen mustards, alkyl sulfonate, nitrosurea, ethylenimine and methylmelamine, triazene classes, cyclophosphamide, ifosamide, thiotepa, melphalan, busulfan, carmustine, clorambucil, hexamethylmelamine and streptozocin.
  • Non-limiting examples of immunosuppressive agents that suppress the immune system includes the corticosteroids, the purine antagonists such as azathioprine, cyclosporine, tacrolimun, sirolimus and mycophenolate mofetil.
  • Non-limiting examples of other active pharmaceutical ingredients potentially useful in the invention include vinca alkaloids such as vincristine and vinblastine; platinum coordination complexes such as cisplatin and carboplatin; isoflavones such as genistein, formomonetin, daidzein and equol; epidophylotoxins such as etoposide and teniposide; camptothecins such as topotecan,and crizecan; folic acid analogues such as methotrexate; pyrimidine analogues such as 5-fluorouracil, floxuridine, and cytosine arabinoside; and purine analogues such as 6-mercaptopurine, 6-thioguanine, and 2-deoxycoformycin; as well as the anti-alcoholism medication disulfiram
  • the density of the compacted sample was approximately 4 g/cm 3 .
  • the high pressure compaction produced a "fused" or “glassy” wafer of olanzapine that was removed from the press.
  • the compacted sample was then forced through a 60 mesh sieve grating with apertures of approximately 250 ⁇ m to produce roughly cuboidal particles.
  • Poly vinyl alcohol (PVA) was obtained with a mol. wt. range of 124,000- 186,000. Excess PVA was heated in water at 65 °C. After cooling, the PVA solution was decanted and mixed with core particles prepared as described above. The core particles were swirled in a beaker of the PVA solution for several seconds, and vacuum-filtered onto #42 filter paper (Whatman, Inc., Clifton, NJ) in a 9 cm diameter Buchner funnel. The filter paper with retained coated core particles was transferred to a watch glass and dried at 155°C or 165°C for 10 minutes. This process was repeated 4-5 times.
  • micronized olanzapine (90% of particles ⁇ 5 ⁇ m in diameter) from a commercial supplier (Dr. Reddy Labs, Upper Saddle River, NJ) was compared with the dissolution of coated microparticles of olanzapine prepared as described above. Powder dissolution testing was carried out in distilled water at 25°C. A 2-3 mg sample of the powder in 25 ml of water was 50% dissolved at approximately 1 minute, and was completely dissolved in 2.5 minutes.
  • Coated microparticle dissolution testing was also carried out in distilled water at 25°C. A 2-3 mg sample was placed in 25 ml of water. The microparticles were completely covered by the solution. Every 24 h for 5 days, 5 ml of the supernatant solution was carefully removed and replaced with fresh media, avoiding mixing of the buffer, to simulate physiological "sink” conditions.
  • Figure 1 represents the data regarding the release of the active pharmaceutical ingredient from the coated microparticles over time. As shown in the figure, the rate of release was substantially constant or pseudo-zero-order over several days. The release rate from the PVA- coated microparticles dried at the lower temperature was greater, indicating that drying temperature can be used to vary permeability and release rate.
  • HPLC high performance liquid chromatography
  • 3-5 male Sprague-Dawley rats were cannulated through the jugular vein to allow venous access.
  • ketamine 60 mg/kg
  • medetomidine 0.3 mg/kg
  • the backs of the rats were shaved and an incision approximately 6 mm in length was made in the skin.
  • the subcutaneous tissues were spread using blunt scissors and 6 mg/kg of the compacted sample was placed into the subcutaneous tissues approximately 5 mm from the incision site. The incision was closed with staples and topical antibiotic applied.
  • Venous samples were taken through the cannula periodically for approximately two weeks to determine plasma levels of the active pharmaceutical ingredients.
  • the assays had sensitivities of approximately 1 ng/ml. Histological examination of the implantation sites was carried out in all animals. Animals appeared to remain healthy and to gain weight normally. By postmortem histological examination of the implantation sites, there was no evidence of local toxicity, tissue reaction or infection.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des procédés pour fabriquer une préparation pharmaceutique de particules fusionnées sous pression comprenant un ingrédient pharmaceutique actif. Les procédés comprennent l'application d'une pression entre 0,1 GPa et 10 GPa pour produire un échantillon compacté. Les particules fusionnées sous pression de l'invention sont conçues pour l'administration parentérale, notamment dans les formulations à libération prolongée grâce à une cinétique de dissolution supérieure à celle des préparations pulvérulentes sous forme cristalline ou amorphe d'ingrédients pharmaceutiques actifs. L'invention concerne également des préparations pharmaceutiques comprenant ces microparticules fusionnées sous pression.
EP03800248A 2002-12-20 2003-12-22 Compactage haute pression pour formulations pharmaceutiques Pending EP1583519A1 (fr)

Applications Claiming Priority (71)

Application Number Priority Date Filing Date Title
US43550502P 2002-12-20 2002-12-20
US43555702P 2002-12-20 2002-12-20
US43503802P 2002-12-20 2002-12-20
US43563002P 2002-12-20 2002-12-20
US43550802P 2002-12-20 2002-12-20
US43550902P 2002-12-20 2002-12-20
US43533602P 2002-12-20 2002-12-20
US43513202P 2002-12-20 2002-12-20
US43510602P 2002-12-20 2002-12-20
US43516302P 2002-12-20 2002-12-20
US43563202P 2002-12-20 2002-12-20
US43503702P 2002-12-20 2002-12-20
US43544902P 2002-12-20 2002-12-20
US43516202P 2002-12-20 2002-12-20
US43537202P 2002-12-20 2002-12-20
US43556502P 2002-12-20 2002-12-20
US43550702P 2002-12-20 2002-12-20
US43550602P 2002-12-20 2002-12-20
US43555802P 2002-12-20 2002-12-20
US43549602P 2002-12-20 2002-12-20
US43541602P 2002-12-20 2002-12-20
US43541502P 2002-12-20 2002-12-20
US43533802P 2002-12-20 2002-12-20
US43544702P 2002-12-20 2002-12-20
US43550102P 2002-12-20 2002-12-20
US43542302P 2002-12-20 2002-12-20
US43548802P 2002-12-20 2002-12-20
US43549702P 2002-12-20 2002-12-20
US43544502P 2002-12-20 2002-12-20
US43538802P 2002-12-20 2002-12-20
US43507502P 2002-12-20 2002-12-20
US43549402P 2002-12-20 2002-12-20
US43549502P 2002-12-20 2002-12-20
US435447P 2002-12-20
US435557P 2002-12-20
US435037P 2002-12-20
US435336P 2002-12-20
US435507P 2002-12-20
US435495P 2002-12-20
US435106P 2002-12-20
US435630P 2002-12-20
US435416P 2002-12-20
US435449P 2002-12-20
US435505P 2002-12-20
US435508P 2002-12-20
US435558P 2002-12-20
US435497P 2002-12-20
US435415P 2002-12-20
US435496P 2002-12-20
US435488P 2002-12-20
US435423P 2002-12-20
US435445P 2002-12-20
US435501P 2002-12-20
US435372P 2002-12-20
US435632P 2002-12-20
US435494P 2002-12-20
US435509P 2002-12-20
US435565P 2002-12-20
US435075P 2002-12-20
US435132P 2002-12-20
US435338P 2002-12-20
US435163P 2002-12-20
US435162P 2002-12-20
US435038P 2002-12-20
US435506P 2002-12-20
US435388P 2002-12-20
US45072203P 2003-02-28 2003-02-28
US450722P 2003-02-28
US45499703P 2003-03-14 2003-03-14
US454997P 2003-03-14
PCT/US2003/041392 WO2004058222A1 (fr) 2002-12-20 2003-12-22 Compactage haute pression pour formulations pharmaceutiques

Publications (1)

Publication Number Publication Date
EP1583519A1 true EP1583519A1 (fr) 2005-10-12

Family

ID=32686487

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03800248A Pending EP1583519A1 (fr) 2002-12-20 2003-12-22 Compactage haute pression pour formulations pharmaceutiques

Country Status (3)

Country Link
EP (1) EP1583519A1 (fr)
AU (3) AU2003299982B2 (fr)
WO (2) WO2004058222A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007049304A2 (fr) * 2005-10-27 2007-05-03 Jubilant Organosys Limited Formulation pharmaceutique enrobee, stable, d'olanzapine et son procede de preparation
GB0522474D0 (en) * 2005-11-03 2005-12-14 Actavis Group A pharmaceutical formulation
ES2279715B1 (es) 2005-12-26 2008-06-01 Laboratorios Lesvi, S.L. Formulacion oral de olanzapina.
CN104159635B (zh) 2012-02-27 2018-09-25 奥雷制药有限公司 用于耳蜗内递送治疗剂以治疗耳部病症的固体药物植入物
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
IL287731B2 (en) 2013-03-21 2025-05-01 Eupraxia Pharmaceuticals USA LLC A sustained-release preparation for injection for the treatment of arthritis and resulting pain
ES2672993T3 (es) * 2015-10-27 2018-06-19 Eupraxia Pharmaceuticals Inc. Formulaciones de liberación sostenida de anestésicos locales

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2515898A (en) 1947-09-15 1950-07-18 Lilly Co Eli Procaine penicillin and therapeutic compositions
US2627491A (en) 1950-07-15 1953-02-03 Wyeth Corp Penicillin salts of substituted alkylene diamines
US3867519A (en) * 1972-04-27 1975-02-18 Alza Corp Bioerodible drug delivery device
US4623588A (en) 1984-02-06 1986-11-18 Biotek, Inc. Controlled release composite core coated microparticles
US5271946A (en) 1988-04-20 1993-12-21 Asta Pharma Aktiengesellschaft Controlled release azelastine-containing pharmaceutical compositions
JPH08337498A (ja) * 1995-04-13 1996-12-24 Sumitomo Electric Ind Ltd ダイヤモンド粒子、ダイヤモンド合成用粒子及び圧密体並びにそれらの製造方法
US6398991B1 (en) * 1998-06-25 2002-06-04 Coorstek, Inc. Processes for making a silicon carbide composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2004058222A1 *

Also Published As

Publication number Publication date
AU2010201138A1 (en) 2010-04-15
WO2004058223A1 (fr) 2004-07-15
AU2003299982A1 (en) 2004-07-22
AU2003299982B2 (en) 2010-04-29
AU2003299983A1 (en) 2004-07-22
WO2004058222A1 (fr) 2004-07-15

Similar Documents

Publication Publication Date Title
US20070218139A1 (en) High Pressure Compaction For Pharmaceutical Formulations
AU2010201138A1 (en) High pressure compaction for pharmaceutical formulations
KR100354702B1 (ko) 약학조성물의제조방법및서방형조성물
AU2019304570B2 (en) Immediate release formulations of cannabinoids
CN1468090A (zh) 缓释药物制剂及其施用方法
EP0675710B1 (fr) Procede de preparation de produits pharmaceutiques a liberation controlee et produits ainsi obtenus
KR100413581B1 (ko) 용융성(fusible)담체를함유하는약제학적조성물및그제조방법
CN100446757C (zh) 未经制粒制备的包含阿伐他汀的药物组合物
JP2005508301A (ja) 制御された凝集
AU2001287349A1 (en) Slow release pharmaceutical preparation and method of administering same
CN109328249A (zh) 含有具有可释放掺杂剂的陶瓷颗粒的纳米纤维垫
WO2005053689A2 (fr) Compositions pharmaceutiques comprenant de la lercanidipine
Rewar et al. Pulsatile drug delivery system: an overview
JP2006528604A (ja) ６−ジメチルアミノメチル−１−（３−メトキシ−フェニル）−シクロヘキサン−１，３−ジオールを含む、有効物質徐放性医薬
CN112190553B (zh) 甲磺酸雷沙吉兰微球制剂及其制备方法
KR20230152051A (ko) 멜라토닌을 포함하는 다층 펠릿의 제형(formulation of a multilayered pellet comprising melatonin)
JP4754485B2 (ja) 共沈活性物質含有粒子
KR101740717B1 (ko) 리스페리돈을 함유하는 서방출성 미립구 및 이의 제조방법.
KR20160027421A (ko) 리스페리돈을 함유하는 서방출성 미립구 및 이의 제조방법.
JP4696210B2 (ja) イソソルビド‐５‐モノニトレートを有効成分とする徐放性錠剤及びその製造方法
MXPA06000111A (es) Proceso para preparar formulaciones de farmacos que regulan lipidos.
HK1088231A (en) Pharmaceutical compositions comprising atorvastatin manufactured without granulation

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20050720

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
18D Application deemed to be withdrawn

Effective date: 20100702

D18D Application deemed to be withdrawn (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

R18D Application deemed to be withdrawn (corrected)

Effective date: 20100630